Hepatitis Clinical Trials in San Antonio

Showing 81-100 of 280 trials

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT03987074

The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).

Nonalcoholic Steatohepatitis

Gilead Sciences109 participantsStarted Jul 2019

Chandler, Arizona, United States • Coronado, California, United States • La Jolla, California, United States +15 more locations

UNKNOWNPhase 2< 1 mile

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

NCT04702490

A randomized, multi-center study evaluating MET409 (50 mg) alone or in combination with empagliflozin (10 mg) for 12 weeks. Assignment to MET409 will be double-blind and placebo-controlled. Empagliflozin will be incorporated into two of the treatment arms in an open-label manner.

NASHNASH - Nonalcoholic SteatohepatitisType 2 Diabetes+5 more

Metacrine, Inc.120 participantsStarted Dec 2020

Fort Myers, Florida, United States • San Antonio, Texas, United States

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Hepatitis Trials in Other Cities

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients

TD-6450 MAD Study in HCV Infected Subjects

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection

A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

Other Conditions in San Antonio